Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands. Stein, D., Joulain, F., Naoshy, S., Iqbal, U., Muszbek, N., Payne, K. A., Ferry, D., & Goey, S. H. International Journal of Colorectal Disease, 29(10):1203–1210, October, 2014.
doi  abstract   bibtex   
PURPOSE: This study aimed to elicit EuroQol Quality of Life 5-Dimensions (EQ-5D) utility values from patients with second-line metastatic colorectal cancer (mCRC) pre- and post-progression. METHODS: A cross-sectional study was conducted in five hospitals in the Netherlands and the UK. Patients with mCRC were eligible if prescribed a second or subsequent line of therapy or best supportive care (BSC), received prior oxaliplatin in first-line therapy, and had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-2 at second-line initiation. Patients completed the EuroQol Quality of Life 5-Dimensions 3-levels (EQ-5D-3L) questionnaire and were categorized as pre- or post-progression. Chart data including patient demographics, clinical history, prior/current treatments and serious adverse events (SAEs) were collected. Mean utilities were estimated; uni- and multivariate analyses were conducted. RESULTS: Seventy-five patients were enrolled; 42 were pre-progression defined as second line or third line following an AE on second line and 33 were post-progression defined as third or subsequent therapy lines or BSC. Patient/disease characteristics and number of SAEs were similar between cohorts. Mean utility scores were 0.741 (SD = 0.230) and 0.731 (SD = 0.292) for pre- and post-progression cohorts, respectively. Compared to pre-progression, more patients reported increased anxiety/depression (36 vs. 12 %) and fewer problems with daily activities (64 vs. 38 %) post-progression. More patients pre-progression were on active treatment at enrolment (83 vs. 42 %) compared to post-progression. CONCLUSIONS: This is the first real-world study to collect utilities for patients with second-line mCRC pre- and post-disease progression. Utility values were similar pre- and post-progression. To further explore the effect of radiological progression on utilities, longitudinal research is required that includes patients in palliative care centres.
@article{stein_assessing_2014-1,
	title = {Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the {United} {Kingdom} and the {Netherlands}},
	volume = {29},
	issn = {1432-1262},
	shorttitle = {Assessing health-state utility values in patients with metastatic colorectal cancer},
	doi = {10.1007/s00384-014-1980-1},
	abstract = {PURPOSE: This study aimed to elicit EuroQol Quality of Life 5-Dimensions (EQ-5D) utility values from patients with second-line metastatic colorectal cancer (mCRC) pre- and post-progression. METHODS: A cross-sectional study was conducted in five hospitals in the Netherlands and the UK. Patients with mCRC were eligible if prescribed a second or subsequent line of therapy or best supportive care (BSC), received prior oxaliplatin in first-line therapy, and had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-2 at second-line initiation. Patients completed the EuroQol Quality of Life 5-Dimensions 3-levels (EQ-5D-3L) questionnaire and were categorized as pre- or post-progression. Chart data including patient demographics, clinical history, prior/current treatments and serious adverse events (SAEs) were collected. Mean utilities were estimated; uni- and multivariate analyses were conducted. RESULTS: Seventy-five patients were enrolled; 42 were pre-progression defined as second line or third line following an AE on second line and 33 were post-progression defined as third or subsequent therapy lines or BSC. Patient/disease characteristics and number of SAEs were similar between cohorts. Mean utility scores were 0.741 (SD = 0.230) and 0.731 (SD = 0.292) for pre- and post-progression cohorts, respectively. Compared to pre-progression, more patients reported increased anxiety/depression (36 vs. 12 \%) and fewer problems with daily activities (64 vs. 38 \%) post-progression. More patients pre-progression were on active treatment at enrolment (83 vs. 42 \%) compared to post-progression. CONCLUSIONS: This is the first real-world study to collect utilities for patients with second-line mCRC pre- and post-disease progression. Utility values were similar pre- and post-progression. To further explore the effect of radiological progression on utilities, longitudinal research is required that includes patients in palliative care centres.},
	language = {eng},
	number = {10},
	journal = {International Journal of Colorectal Disease},
	author = {Stein, D. and Joulain, F. and Naoshy, S. and Iqbal, U. and Muszbek, N. and Payne, K. A. and Ferry, D. and Goey, S. H.},
	month = oct,
	year = {2014},
	pmid = {25080148},
	keywords = {Activities of Daily Living, Antineoplastic Agents, Anxiety, Colorectal Neoplasms, Cross-Sectional Studies, Depression, Disease Progression, Female, Humans, Male, Middle Aged, Netherlands, oncology, Organoplatinum Compounds, Oxaliplatin, Pain, Palliative Care, Quality of Life, Surveys and Questionnaires, United Kingdom},
	pages = {1203--1210},
}

Downloads: 0